Jiayuh Lin PhD

Jiayuh Lin PhD
Assoc ProfessorCollege of MedicineJiayuh.Lin@nationwidechildrens.org
WA5020 Center for Childhood Cancer - CCRI 700 Children's Drive Columbus OH 43205
Phone:(614) 722-5086Fax: (614) 722-5868
  • Translational Therapeutics

General Research Interest

Our laboratory is working on the cancer biology and cancer therapy of STAT3 pathway in human cancer.

Research Description

Dr. Lin’s research is focused on evaluating the effects of dietary agents in fruits and vegetables including ursolic acid, sulforaphane, curcumin, quercetin, capsaicin, and others either by single agent alone or in combination on the IL-6/STAT3 signaling pathway in human cancer cells. The ultimate goal is to use this knowledge to develop novel therapeutic approaches for patients with cancer and improve upon existing therapies as well as to develop chemo-preventative approaches to potentially reduce cancer incidence.

Transinstitutional Work

Collaborators to develop novel STAT3 and IL-6 inhibitors: Tom Li, Ph.D. (Division of Medicinal chemistry, College of Pharmacy) Chenglong Li, Ph.D. (Division of Medicinal chemistry, College of Pharmacy) Jim Fuchs, Ph.D. (Division of Medicinal chemistry, College of Pharmacy) Gregory Lesinki, Ph.D. (Internal Medicine, College of Medicine)

Current Publications

  • Li H, Xiao H, Lin L, Jou D, Kumari V, Lin J, Li CDrug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.J Med Chem 57 632-41 2/13/2014
  • Bid HK, Roberts RD, Cam M, Audino A, Kurmasheva RT, Lin J, Houghton PJ, Cam HΔNp63 promotes pediatric neuroblastoma and osteosarcoma by regulating tumor angiogenesis.Cancer Res 74 320-9 1/1/2014
  • Kurmasheva RT, Mo X, Fernandez S, Houghton PJ, Bid HK, Kibler A, Phelps DA, Manap S, Xiao L, Lin J, Capper D, Oswald D, Geier B, DeWire M, Smith PDDevelopment, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.Clin Cancer Res 19 6716-29 12/15/2013
  • Li L, Tang W, Wu X, Karnak D, Meng X, Thompson R, Hao X, Li Y, Qiao XT, Lin J, Fuchs J, Simeone DM, Chen ZN, Lawrence TS, Xu LHAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s.Clin Cancer Res 19 6703-15 12/15/2013
  • Wang W, Zhao C, Jou D, Lü J, Zhang C, Lin L, Lin JUrsolic acid inhibits the growth of colon cancer-initiating cells by targeting STAT3.Anticancer Res 33 4279-84 10/1/2013
  • Yu W, Xiao H, Lin J, Li CDiscovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.J Med Chem 56 4402-12 6/13/2013
  • Lin L, Hutzen B, Lee HF, Peng Z, Wang W, Zhao C, Lin HJ, Sun D, Li PK, Li C, Korkaya H, Wicha MS, Lin JEvaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells.PLoS One 8 e82821 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu